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Feeling Lightheaded: The Role of Cerebral Blood Flow
JOHAN BRESSELEERS, MA, ILSE VAN DIEST, PHD, STEVEN DE PEUTER, PHD, PETER VERHAMME, MD, PHD,
AND OMER VAN DEN BERGH, PHD
Objective: The main aims of this study were a) to investigate the relationship between lightheadedness and cerebral blood flow
velocity (CBFv) during hyperventilation-induced hypocapnia, and b) to investigate whether and why the relationship between
lightheadedness and CBFv may change after several episodes of this sensation.Methods: Three hypocapnic and three normocapnic
overbreathing trials were administered in a semirandomized order to healthy participants (N 33). Each type of breathing trial was
consistently paired with one odor. Afterward, participants were presented each odor once in two spontaneous breathing and in two
normocapnic overbreathing trials. CBFv in the right middle cerebral artery was measured by transcranial Doppler ultrasonography
(TCD). Also breathing behavior and self-reported lightheadedness were measured continuously. Each trial was followed by a
symptom checklist. Results: Self-reported lightheadedness was closely related to changes in CBFv in the hypocapnic overbreathing
trials. During the subsequent normocapnic trials, however, participants experienced more lightheadedness and “feeling unreal” to
the odor that had previously been paired with hyperventilation-induced hypocapnia. These complaints were not accompanied by
changes in end-tidal CO2 nor in CBFv. Conclusions: The results show that lightheadedness is associated with changes in CBFv
but that after a few episodes, the underlying mechanism for this symptom may shift to perceptual-cognitive processes. These
findings may help to understand why lightheadedness occurs during emotional distress and panic. In addition, altered cerebral blood
flow is unlikely to play a primary precipitating role in recurrent symptoms of lightheadedness. Key words: lightheadedness,
pseudoneurological complaints, cerebral blood flow, hyperventilation, conditioning, transcranial Doppler.
Abbreviations: PNC  pseudoneurological complaints; IEI  idio-
pathic environmental illness; CBF  cerebral blood flow; CBFv 
cerebral blood flow velocity; CS  conditioned stimulus; US 
unconditional stimulus; TCD  Transcranial Doppler ultrasonogra-
phy;MCAmiddle cerebral artery; VAS Visual Analogue Scale;
Vi inspiratory volume; FetCO2 fractional end-tidal CO2; Vm
intensity weighted mean blood flow velocity in the right middle
cerebral artery.
INTRODUCTION
The term pseudoneurological complaints (PNCs) is oftenused in psychosomatic medicine to refer to complaints
such as lightheadedness or dizziness, concentration problems,
feelings of dissociation/derealization, numbness, weakness,
difficulties concentrating, poor memory, and fatigue without a
clear medical explanation, although the set of symptoms is not
clearly defined (i.e., the term PNC has been used inconsis-
tently to refer to [subsets of] a variety of somatic and cognitive
complaints [1–3]). They have been documented to relate to
stress and anxiety (1,4). In addition, PNCs show a strong
overlap with symptoms seen in idiopathic environmental ill-
ness (IEI)/multiple chemical sensitivity, posttraumatic stress
disorder, panic disorder, and several “functional syndromes”
such as chronic fatigue syndrome (3–9). In this study, we
focus on processes underlying lightheadedness, a cardinal
symptom of hyperventilation which itself has been frequently
reported in IEI and panic disorder (5,10–15). Lightheadedness
is assumed to be caused by cerebral ischemia (a decrease in
cerebral blood flow [CBF]) as a result of hyperventilation-
induced hypocapnia (16). However, the relationship between
changes in CBF and changes in lightheadedness during hy-
perventilation has not been investigated in detail. In addition,
previous work of our group has demonstrated that repeated
symptom episodes in association with specific cues produces
learning that may alter the relationship between a symptom
and its underlying physiological cause. For example, in a
differential conditioning paradigm, harmless odors (condi-
tioned stimuli [CSs]) were mixed with CO2-enriched air (un-
conditional stimulus [US]) during a number of breathing trials
and subsequently presented alone (17). This resulted in ele-
vated symptom reports during the presentation of the odor
previously paired with the CO2 inhalation, indicating a learn-
ing effect.
Hyperventilation has been discredited as an explanation for
a wide variety of symptoms that were attributed to it after it
was found that such symptoms did not temporally coincide
with hypocapnic episodes (18,19). However, the critical role
of hyperventilation may be restored by this learning account
when assuming that repeated symptom episodes may change
the relationship between a symptom and its underlying cause.
Earlier, we administered hyperventilation-induced hypocapnia
as a US inducing symptoms including lightheadedness,
whereas specific but harmless odor cues were added to the
breathing circuit as CSs (5). Afterward, participants felt
more unreal and reported lightheadedness quicker in re-
sponse to the specific odor that had been presented together
with the hypocapnic episode. This was not accompanied by
any concomitant differences in end-tidal CO2 (5). Volun-
tary hyperventilation can be seen as a laboratory analogue
for real-life hyperventilation episodes, which are highly prev-
alent in anxiety and nonclinical states of stress (20–23). In that
respect, these hypocapnic challenges may have a wider rele-
vance than hypercapnic ones. In our laboratory model, odors
were used as CSs, and voluntary hyperventilation was a US.
However, in real life, hyperventilation may be elicited by
stress and anxiety, so that cues associated with these condi-
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tions may function as CSs and induce symptoms on subse-
quent occasions.
An important remaining question is what mechanism un-
derlies learned lightheadedness. Two explanations have been
put forward (5). First, symptom perception processes could
account for the experience of the learned complaint. Several
models of symptom perception and medically unexplained
symptoms assign a significant role to memory representations
in the generation of a perceptual experience (24,25). Second,
the presence of learned lightheadedness can be related to a
conditioned cerebral vasoconstriction/cerebral ischemia, even
in the absence of hypocapnia. Several observations make the
latter speculation viable: a) Pavlovian conditioning of vascular
responses has been reported in several studies (26–28), b)
altered CBF reactions to blood level of CO2 changes have
been found in panic disorder patients (29–31), and c) cerebral
arterioles have been shown to be innervated by sympathetic
neurons, and although the influence of sympathetic activation on
CBF has been the topic of discussion (32), sympathetic activation
has been shown to induce cerebral vasoconstriction (33–35).
The aims of this study were to investigate the relationship
between CBF velocity (CBFv) and lightheadedness during
periods of hyperventilation and to investigate whether learned
lightheadedness in response to chemical cues is accompanied
by decreases in CBFv. Transcranial Doppler ultrasonography
(TCD) was used to measure CBFv in the right middle cerebral
artery (MCA). TCD is a validated technique to measure mean
and regional CBFv (36–41), which has often been used to
assess reactivity to changes in CO2 (42,43). We hypothesized
that a) lightheadedness is strongly related with CBF during
hyperventilation in the first place, and b) after a few learning
episodes, odors previously paired with hypocapnia (CS)
would induce more lightheadedness compared with odors
previously paired with normocapnia (CS) without concom-
itant differences in end-tidal CO2. Regarding CBF, we ex-
plored whether the acquired lightheadedness would be related
to a decreased CBFv during CS in a test phase as a result of
conditioned cerebral vasoconstriction.
METHODS
Participants
Thirty-six university students, recruited using a mailing list, volunteered
to participate in return for 12€. Exclusion criteria were self-report of: alcohol
consumption 6 hours before the experiment, disease, (history of) psycholog-
ical or psychiatric disorder, (history of) migraine, and medication use (except
for contraceptives). Two participants were excluded because of technical
issues (capnograph failure and insufficient Doppler signal power, respec-
tively) and one because of failure to comply with the hyperventilation in-
structions. This resulted in a study sample of 33 participants (29 women,
mean age 18.6 years). The experiment was approved by the Ethics Commit-
tees of the Department of Psychology and of the Faculty of Medical Sciences.
The data were collected between December 2007 and February 2008.
Materials
Materials and measures used were partly the same as used in a previous
study of this group (5). Only the most important and new features are
discussed in this study.
Self-Report Measures
During each trial, participants continuously rated lightheadedness on a
vertical computerized Visual Analog Scale (VAS, 0–100) using a keyboard.
Other complaints were assessed after each trial using an adapted version of the
Checklist for Psychosomatic Symptoms (5,44), consisting of complaints be-
longing to one of eight subsets: anxiety, dizziness, cardiac, gastrointestinal,
paresthesia, respiratory, dummy, and unclassified complaints, together with
two added hyperventilation complaints (lightheadedness and feeling unreal).
Dummy complaints were four sensations that are rarely associated with
hyperventilation (nasal congestion, joint pain, low back pain, and burning
eyes) to control for response biases.
Apparatus
The setup of the breathing circuit, apparatus calibration, and parameter
extraction were predominantly based on a previous study of our group (5). To
this breathing circuit, a bacterial filter (Microgard, Viasys Heathcare) was
added, which was placed on the mask to avoid sample line occlusion by
condensation from expired air. In addition, a second capnograph was added to
the original breathing circuit (Capnoguard ETCO2 Monitor, Novametrix
Medical Systems Inc., USA). This capnograph sampled expired air from the
expiratory tube and was used in the normocapnic overbreathing trials because
the administration of CO2 influenced the online estimation of end-tidal CO2
with air sampled near the mask. Both capnographs were calibrated before
each experimental session using a calibration gas containing 7.5% CO2; the
pneumotachograph was calibrated using a calibrated syringe (Calibration
Pump 1L, Viasys Healthcare GmbH, Germany). The CO2 and flow signal
(transformed offline into a volume signal) were processed with a Labmaster
card (Labmaster DPCI, Scientific Solutions) at a sampling rate of 100 Hz and
stored on personal computer using Affect (Affect 4 [45]).The following
parameters were calculated for each breathing cycle: respiratory rate (breath-
ing frequency, breaths/min), inspiratory volume (Vi, ml), inspiratory drive
(ml/s), and fractional end-tidal CO2 (FetCO2, %). Odors (0.8% ammonia,
7.4% acetic acid)1 were dispersed at a rate of 3 liters/min using a nebulizer
(Sidestream, Respironics) connected to the mask. A mixture of 35% CO2
(21% O2 and 44% N2) was administered at a variable flow rate into the
inspiratory tube during normocapnic breathing trials (see later).
A TCD (Doppler box, DWL) measured CBFv (sampled at 100 Hz) in the
right MCA with a 2-MHz probe. One limitation is that CBFv is measured
instead of CBF, making its reliability dependent on the constancy of the
diameter of the insonated artery. In support of this assumption, several studies
have shown that the MCA remains relatively constant during hyper and
hypocapnia (46–48). Second, because the measure depends on the angle
between the probe and the insonated artery (49), the probe was fixed using a
headband device (Marc 600, Spencer Technologies), and only relative values
were used. Specific software (QL software, DWL) was used to calculate
intensity weighted mean velocity (Vm).
Procedure
On arrival, participants were screened for the exclusion criteria. Next, they
read a cover story explaining that this study investigated the effects of
cleaning products for air conditioning systems on several complaints. The text
explained that participants would receive one of two possible air mixtures in
each trial and that the air mixtures could possibly induce complaints. It was
assured that the mixtures were not harmful and that eventual complaints
would be of low intensity and transient. Participants consenting to participate
provided written informed consent. The use of the computerized VAS was
then illustrated explaining that “0” represented no lightheadedness and “100”
the maximum lightheadedness one could experience. Finally, subjects were
told that in most trials they would have to breathe as deeply as possible on the
rhythm of a metronome. This was demonstrated by the experimenter. After
the instructions, the right MCA was insonated through the right temporal
window just above the zygomatic arch using a standard technique (50), at a
range of depth between 45 and 55 mm. The Doppler signal was optimized by
increasing the sample depth in a stepwise manner and changing the angle of
the probe. Once the optimal signal was obtained, the probe was secured onto
the headband.
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The experiment contained several overbreathing and spontaneous breath-
ing trials. Each trial consisted of 10 seconds of nose breathing, followed by 80
seconds of mouth breathing. This was done to ensure odor perception. A
five-minute recovery, during which participants completed the symptom
checklist, followed each trial. In the overbreathing trials, participants were
instructed to breathe as deeply as possible at the pace of a metronome,
targeted at 30 breaths/min. During the trials, the experimenter instructed the
participants over an intercom system to breathe as deeply as possible and to
follow the metronome as closely as possible.
The experiment used a typical differential conditioning paradigm, con-
sisting of a training and test phase (Figure 1). The training phase consisted of
three hypocapnic overbreathing trials and three normocapnic overbreathing
trials, which were presented in semirandomized order with no more than two
consecutive trials of the same type. One odor was paired with the hypocapnic
overbreathing trials (CS); the other with the normocapnic overbreathing
trials (CS). Additionally, two on-screen labels were used to increase CS/
CS differentiation (“zeumhydride” and “nialinecitraat”). During CS, 35%
CO2-enriched air was added into the inspiratory tube at an experimenter-
controlled flow rate to maintain normocapnia. The normocapnic target value
of FetCO2 was determined individually during a baseline trial before training.
The pairing of the odors and labels with either a CS or a CS trial was
randomized over participants. The test phase consisted of two blocks in
randomized order: a block consisting of two spontaneous breathing trials and
a block with two normocapnic overbreathing trials. Within each block, the
first trial was always presented with a CS odor-label pair and the second
trial with CS.
Data Reduction and Analysis
Three parameters were calculated based on the online measure of light-
headedness: the time elapsed before the first lightheadedness (TEBL), calcu-
lated as the time before participants rated lightheadedness; the maximal
intensity of lightheadedness rated by participants during a trial; and the mean
intensity of lightheadedness after the first rating.
The posttrial items lightheadedness and feeling unreal were analyzed
separately. For the other symptom items of the posttrial questionnaire, anal-
ysis was done by subgroup. Before respiratory parameter calculation, irreg-
ular and shallow breaths not reaching an end-tidal alveolar plateau (1% of
all breaths) were rejected. Afterward, averages of each respiratory parameter
for each 10-second interval were calculated with each breath weighted for its
relative time occupied in the interval. For Vm, a percentage change to baseline
was calculated and averaged for each 10-second interval in the same manner
as the breathing parameters. For Vm and online lightheadedness, 5-second
intervals were also calculated, which were used to determine the correlation
between both measures in training and test CS trials.
Data from training and test phases were analyzed separately. The six
overbreathing trials of the training phase were analyzed in a CS odor
(ammonia, acetic acid)  CS (CS, CS)  trial (first, second, third) 
interval (1–8, for breathing and CBFv data) repeated measures analysis of
variance. The two overbreathing and spontaneous breathing test trials were
each analyzed in a CS odor (ammonia, acetic acid)  CS (CS, CS) 
interval (1–8, for breathing and CBF data) analysis of variance. All statistics
will be reported for time elapsed before the first lightheadedness, mean, and
maximum intensity of lightheadedness. The description of the results will
primarily focus on significant patterns, and the data are presented in the tables.
Greenhouse-Geisser corrections were applied when appropriate. Furthermore,
we computed ƒ2 effect sizes. Cohen (51) described values of 0.02, 0.15, and
0.35 as small, medium, and large, respectively.
RESULTS
Training
Online Lightheadedness
Compared with CS, participants did not experience light-
headedness quicker during CS (Table 1). Participants did
experience lightheadedness earlier in the first trial compared
with the third (Tukey honestly significant difference [HSD]
test p  .013) and tended to have lightheadedness earlier in
the first compared with the second trial (Tukey HSD test p 
.057). The maximum lightheadedness was higher during CS
compared with CS and was also higher in the third trial
compared with the first (Tukey HSD test p .022). The mean
lightheadedness was higher during CS compared with the
CS training trials. In addition, the mean lightheadedness
tended to be higher in the third trial compared with the first
(F(2,62)  2.95,   0.94, p  .063, ƒ2  0.07, Tukey HSD
test p  .061).
Complaints
For the training trials, participants reported more lighthead-
edness and “feeling unreal” during CS compared with CS
trials (Table 1). For lightheadedness, the main effect of trialFigure 1. Schematic representation of the study design.
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was also significant and the CS  trial interaction. Further
analysis of this interaction showed that participants rated less
lightheadedness in the first CS trial compared with the
following two CS trials (Tukey HSD test, all p values 
.001); no such differences were found for CS trials.
Except for the dummy (nasal congestion, joint pain, low
back pain, and burning eyes) and gastrointestinal symptoms,
all scores on the symptom subgroups were higher for CS
training trials compared with CS. Participants also rated less
unclassified complaints in the first trial compared with the
other trials (Tukey HSD test, Trial 2: p  .012; Trial 3: p 
.001). For cardiac symptoms and dizziness, the main effect of
trial and the CS  trial interaction were significant. Further
analysis of these interactions showed an increase in dizziness
and cardiac symptoms in the third compared with the first two
CS trials (Tukey HSD test, dizziness: all p values  .001;
cardiac: Trial 1: p  .002, Trial 2: p  .001); no differences
were found for CS trials.
Breathing
As a result of the manipulation, significant effects were
observed of CS, interval, and CS interval for FetCO2 during
training, all in the expected direction (Table 2). In addition,
FetCO2 was lower in the last two CS trials compared with
the first (Tukey HSD test, p  .001), whereas no such de-
crease was observed for CS trials. Finally, the trial 
interval interaction also reached significance. Further analysis
of this interaction showed that, for all intervals except for the
last two, FetCO2 was lower in the first trial compared with the
second trial (Tukey HSD, interval 4: p  .007, interval 5: p 
.005, all other intervals: p  .001) and the third (Tukey HSD,
all p values  0.001) trials. Although FetCO2 was lower
during CS compared with baseline, this pattern of results
indicates a successful within subject control for hypocapnic
overbreathing in the normocapnic overbreathing trials.
In line with the FetCO2 decrease over trials, participants
breathed deeper during the last two trials compared with the
first (Tukey HSD test all p values  .001). Furthermore,
inspiratory volume increased during the course of the trial but
only in the first two trials (Trial 1 linear trend: t(31)  6.58,
p  .001; Trial 2 linear trend: t(31)  2.71, p  .011).
Cerebral Blood Flow
The Vm results largely paralleled those of FetCO2. Signif-
icant results in the expected direction were found for CS,
interval, and CS  interval (Table 2). In addition, the trial
main effect was significant and the CS  trial interaction.
Tukey comparisons indicate that Vm was higher in the first
CS trial compared with the following CS trials (all p
values  .001). Finally, the trial  interval interaction also
reached significance. Compared with the other trials, Vm
decreased slower in the first trial, which is indicated by a
significant difference in Tukey contrasts for the first three
intervals of the first trial compared with same intervals of the
second and third trial (Tukey HSD test p values  .001). The
within-subject correlation between lightheadedness and Vm
during the trials was high and overall significant (mean:
0.64, standard deviation [SD]: 0.17, significant in 90% of
the cases).
Overbreathing Test Trials
Online Lightheadedness
Participants tended to experience lightheadedness sooner
during the CS test trial compared with CS (F(1,31) 
3.97, p  .055, ƒ2  0.13) (Table 3). Furthermore, during
CS, the maximum rated lightheadedness was significantly
higher. No differences were found between CS and CS in
mean lightheadedness.
Complaints
A significant learning effect was found for lightheadedness
and dizziness (Table 3). Participants also tended to rate more
anxiety in the CS trial (F(1,31)  3.39, p  .075, ƒ2 
0.11). No significant differences were found for the other
symptom subscales.
Breathing
For FetCO2, interval reached significance, indicating that
FetCO2 did not remain constant (Table 3). Further analysis of
this effect does not reveal a linear decrease in FetCO2 (linear
trend: t(31)  0.87, p  .39). There was, however, no signif-
icant main difference between the CS and CS trial nor an
interaction between CS and interval.
Breathing frequency tended to be lower in CS trials
(F(1,31) 3.62, p .066, ƒ2 0.04), although the difference
was minimal. Participants also breathed deeper during CS
trials. For inspiratory volume, the effect of interval tended to
be significant (F(7,217)  2.23,   0.58, p  .068, ƒ2 
0.09). Further analysis of this effect showed no linear trend
(t(31)  0.88, p  .388), only a difference between the first
and fifth interval (Tukey HSD, p  .020).
Cerebral Blood Flow
The changes in Vm parallel those of FetCO2: only the
effect of interval reached significance. Further analysis of this
effect showed a significant linear increase in Vm (linear trend:
t(31)  6.19, p  .001) (Table 3). The within-subject corre-
lation between lightheadedness and Vm did not reach signif-
icance in any participant (mean: 0.04, SD: 0.24).
Spontaneous Breathing Test Trials
Online Lightheadedness
Participants experienced lightheadedness earlier during
CS compared with the CS trial (Table 3). However, no
significant differences were found in mean and maximum
rated lightheadedness.
Complaints
A significant learning effect was found for lightheadedness
and feeling unreal (Table 3). Furthermore, participants scored
higher in the CS trials on the anxiety and cardiac subscales.
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Breathing
FetCO2 decreased during trials (linear trend: t(31) 
5.11, p .001) (Table 3). Furthermore, FetCO2 tended to be
lower during CS compared with CS (F(1,31)  3.20, p 
.084, ƒ2  0.18). Apart from FetCO2, no significant effects
were found on breathing parameters during the spontaneous
breathing trials.
Cerebral Blood Flow
Vm decreased during trials (linear trend: t(31)  2.90,
p  .007) (Table 3). The correlation between lightheadedness
and Vm did not reach significance in any participant (mean:
0.00, SD: 0.21).
DISCUSSION
The main aims of this study were to investigate the rela-
tionship between CBFv and lightheadedness during hyperven-
tilation and to investigate the processes underlying learned
lightheadedness, namely whether it was accompanied by con-
ditioned changes in CBFv. To investigate this, we used a
differential learning paradigm with hypocapnic overbreathing
as US and normocapnic overbreathing as a within-subject
control. Diluted ammonia and acetic acid served as CSs,
together with on-screen labels of fictitious chemicals. In this
paradigm, we measured breathing behavior and used TCD to
measure CBFv in the right MCA. Our findings showed a
lower FetCO2 during hypocapnic overventilation compared
with the normocapnic trials. Although FetCO2 was lower than
baseline during the normocapnic training trials, it was sub-
stantially higher than the levels that are generally reported as
the limit below which complaints such as lightheadedness
occur (around 2.8% FetCO2 [52]), indicating a successful
normocapnic control. This resulted in significant differences
in CBFv and in complaints: CBFv was lower, and participants
rated more lightheadedness during CS training trials com-
pared with CS. Participants also rated all symptom subscales
higher for the CS compared with CS trials, except for
dummy and gastrointestinal complaints. In addition, regarding
the first aim of our study, we found evidence for an overall
strong (linear) relationship between lightheadedness and
CBFv during hypocapnic overventilation.
In the subsequent test phase, several learning effects were
observed. First, a learning effect was found on the online and
the posttrial ratings of lightheadedness in the normocapnic
overbreathing test. In the spontaneous breathing test, a similar
effect occurred for the posttrial questionnaire, and participants
rated lightheadedness sooner during the CS trial on the
online scale. Second, learning effects were also observed on
other complaint subscales, i.e., dizziness in the overbreathing
test, and anxiety and cardiac complaints, and “feeling unreal”
in the spontaneous breathing test.
These results indicate that lightheadedness (and other self-
reported symptoms) can be acquired after a few learning trials,
which documents the robustness of the findings of Van Diest
TABLE 3. Means (Standard Deviations) and Significant Effects of Complaints, Respiration, and CBF Velocity During Test (N  33)
Measure
Overbreathing Test Spontaneous Breathing Test
CS CS Statistics (F, p, f2) CS CS Statistics (F, p, f2)
LH-online
TEBL 41.18 (37.58) 54.65 (33.14) — 42.93 (38.69) 60.21 (35.23) CS (5.87,.021,0.19)
Mean 11.42 (11.44) 8.15 (9.97) — 7.01 (8.43) 6.85 (8.45) —
Max 18.55 (20.68) 10.76 (12.31) CS (5.33,.028,0.13) 11.06 (14.32) 8.27 (8.96) —
Complaints
Lightheadedness 2.21 (0.93) 1.61 (0.66) CS (18.86,.001,0.61) 2.00 (0.97) 1.55 (0.67) CS (12.02,.002,0.39)
Feeling unreal 1.58 (0.97) 1.45 (0.79) — 1.39 (0.66) 1.15 (0.57) CS (5.39,.027,0.17)
Anxiety 1.39 (0.57) 1.29 (0.59) — 1.28 (0.55) 1.13 (0.25) CS (4.77,.037,0.15)
Cardiac 1.39 (0.46) 1.36 (0.48) — 1.30 (0.39) 1.18 (0.31) CS (11.26,.002,0.36)
Dizziness 1.37 (0.45) 1.23 (0.44) CS (7.97,.008,0.26) 1.26 (0.38) 1.15 (0.28) —
Dummy 1.13 (0.23) 1.13 (0.19) — 1.17 (0.25) 1.13 (0.18) —
Gastrointestinal 1.14 (0.25) 1.15 (0.34) — 1.10 (0.25) 1.08 (0.23) —
Respiratory 1.65 (0.60) 1.48 (0.53) — 1.36 (0.49) 1.13 (0.23) —
Paresthesia 1.19 (0.42) 1.18 (0.40) — 1.14 (0.33) 1.12 (0.25) —
Unclassified 1.31 (0.35) 1.27 (0.34) — 1.24 (0.35) 1.22 (0.31) —
Respiration
FetCO2 4.11 (0.34) 4.08 (0.37) INT (3.80,.005,0.13) 3.66 (0.49) 3.75 (0.52) INT (14,59,.001,0.71)
Vi 2223.92 (613.54) 2130.96 (565.76) CS (6.37,.017,0.21) 744.22 (299.60) 753.90 (317.36) —
Freq 29.39 (1.58) 29.71 (1.39) — 18.82 (5.04) 18.73 (4.36) —
CBF
Vm 17.71 (10.77) 18.07 (12.59) INT (20.07,.001,1.16) 14.42 (13.01) 13.70 (12.59) INT (7.95,.001,0.45)
LH-online  online lightheadedness; TEBL  time elapsed before lightheadedness; Mean  mean lightheadedness; Max  maximum rated lightheadedness;
FetCO2  fractional end-tidal CO2; Vi  inspiratory volume; freq  breathing frequency; CBF  cerebral blood flow; Vm  percentage change mean velocity;
CS  odor previously paired with hypocapnia; CS  odor previously paired with normocapnia; statistics:   0.05; CS  conditioned stimulus
(CS–CS); INT  interval (1–8).
df for F statistics: CS  1:31, INT  7:217.
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et al. (5) and corroborates them by showing that learning
processes did not only influence the time of onset but also the
experienced intensity. Although the intensity of acquired
lightheadedness was mild, it is important to note that it took
only three learning trials and that also the US (hypocapnia)
was relatively mild. Our specific operationalization with hy-
perventilation-induced hypocapnia is potentially important be-
cause (1) it explains the inconsistent relationship between
typical hyperventilation-related complaints and hypocapnia
(which has been used to discard the role of hyperventilation
altogether [5,18,19]), and (2) it can function as a laboratory
analogue for real-life hyperventilation as a result of stress or
anxiety. In the latter case, stress/anxiety may trigger hyper-
ventilation as a US, whereas cues related to stress/anxiety and
the context may become CSs for symptoms on subsequent
occasions.
Although participants breathed deeper during CS in the
overbreathing test, the learning effects on complaints were not
paralleled by decreases in FetCO2 nor CBFv. In contrast to
acquisition, the increased lightheadedness during CS was
not related to any changes in CBFv. These results indicate that
the complaints emerged in the absence of the physiological
cause that initially had caused them, favoring symptom per-
ception processes as an explanation, which is in line with a
previous study (53). In that study, a distraction task was used
during the training phase of a differential odor-CO2 condition-
ing paradigm. Learned complaints were modulated by the atten-
tion manipulation during the training phase and were unrelated to
actual physiological responses during the test phase, indicating
that learned complaints are based on activated information in
memory. Obviously, repeated experiences of complaints in a
particular context lead to the development of memory represen-
tations, which can subsequently be triggered by associated cues
and bias the interoceptive experience of the body (see also
Refs. 24, 25, and 54–56).
In conclusion, the results of this study demonstrate a strong
relationship between CBF and lightheadedness during hyper-
ventilation. However, this relationship may change across a
few symptom episodes: lightheadedness became unrelated to
physiological changes in FetCO2 or CBFv, suggesting that its
emergence became dependent on perceptual-cognitive pro-
cesses or in other words, “medically unexplained.” Our find-
ings underline the value of a perceptual-cognitive learning
model for lightheadedness. Clinical studies are needed to
document whether this learning account may explain part of
the symptoms in several pathologies such as IEI, posttrau-
matic stress disorder, panic disorder, and several “functional
syndromes.”
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